Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Hamburg | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Santiago | USD | Delayed | ||
| Buenos Aires | ARS | Delayed | ||
| BM&FBovespa | BRL | Delayed | ||
| Vienna | EUR | Delayed | ||
| KASE | USD | Delayed | ||
| Colombia | COP | Delayed | ||
| Lima | USD | Delayed |
Citi lowered the price target on McDonald's (MCD) to $277.00 from $279.00 while maintaining a Neutral rating. McDonald's reported its Q4 results today, with top and bottom-line...
By Ahmed Aboulenein WASHINGTON (Reuters) - The U.S. government on May 11 will end the COVID-19 Public Health Emergency (PHE) that allowed millions of Americans to receive...
Fed rate decision, Mega-cap tech earnings, U.S. jobs report in focus. Caterpillar shares are a buy amid strong profit and sales growth. Peloton stock set to underperform amid...
Global drug spending is set to reach $1.9 trillion by 2027. Pfizer remains well-positioned to capture much of this. A price-to-earnings ratio of just 8.7 suggests the stock is...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
| Average | 54.30 (+22.96% Upside) |
| High | 75.00 |
| Low | 44.00 |
| Price | 44.16 |
| No. of Analysts | 20 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Sell | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 116.01 | 116.40 | 110.43 | +2.45 | +2.16% | 27.72M | NYSE | |||
| 44.16 | 44.28 | 42.70 | +0.61 | +1.40% | 49.47M | NYSE | |||
| 103.13 | 103.35 | 101.14 | +2.58 | +2.57% | 65.20M | NASDAQ | |||
| 11.45 | 11.83 | 11.38 | -0.28 | -2.39% | 19.80K | NYSE | |||
| 148.97 | 149.88 | 147.52 | +1.91 | +1.30% | 28.87M | NASDAQ | |||
| 5.35 | 5.35 | 5.00 | +0.34 | +6.79% | 21.61M | NYSE | |||
| 92.73 | 92.76 | 90.00 | -0.40 | -0.43% | 13.28M | NYSE | |||
| 64.79 | 64.79 | 63.63 | +0.66 | +1.03% | 10.15M | NYSE | |||
| 72.19 | 72.50 | 67.43 | +6.22 | +9.43% | 1.69M | NYSE | |||
| 65.44 | 65.48 | 64.71 | +0.60 | +0.93% | 5.87M | NASDAQ | |||
| 173.22 | 174.30 | 162.78 | +6.56 | +3.94% | 195.89M | NASDAQ | |||
| 134.73 | 135.65 | 133.76 | -0.57 | -0.42% | 7.17M | NYSE | |||
| 129.28 | 129.73 | 126.96 | +1.49 | +1.17% | 4.31M | NYSE | |||
| 60.30 | 60.34 | 58.65 | -1.41 | -2.28% | 23.71M | NASDAQ | |||
| 100.27 | 104.70 | 99.13 | -6.15 | -5.78% | 7.77M | NYSE |